-+ 0.00%
-+ 0.00%
-+ 0.00%

AIM ImmunoTech Q3 2026 net loss narrows 6% to $3.1 million

PUBT·11/13/2026 13:31:59
Listen to the news
AIM ImmunoTech Q3 2026 net loss narrows 6% to $3.1 million
  • AIM ImmunoTech’s third-quarter 2026 net loss narrowed 6% year over year to approximately $3.1 million.
  • Cash, cash equivalents and marketable securities more than doubled to approximately $6.9 million at September 30, 2026, from December 31, 2025.
  • Research and development expenses rose 39% year over year to approximately $846,000, primarily reflecting Ampligen precursor manufacturing costs.
  • Ampligen dosing in Phase 2 DURIPANC concluded, with topline pancreatic cancer results expected in Q1 2027 to inform pivotal Phase 3 development.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AIM ImmunoTech Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611130830PRIMZONEFULLFEED9876975) on November 13, 2026, and is solely responsible for the information contained therein.